← Back to Clinical Trials
Recruiting NCT06404684

NCT06404684 Psychological Treatment for Paraphilic Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06404684
Status Recruiting
Phase
Sponsor Region Stockholm
Condition Paraphilic Disorders
Study Type INTERVENTIONAL
Enrollment 14 participants
Start Date 2025-03-04
Primary Completion 2027-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cognitive behavioral therapy (CBT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 14 participants in total. It began in 2025-03-04 with a primary completion date of 2027-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this randomized study is to learn if a psychological intervention can treat help-seeking patients with paraphilic disorders. The main questions it aims to answer are: 1. Is psychological therapy helpful for the reduction of problematic sexual behaviors among patients with paraphilic disorders? 2. Is psychological helpful for the reduction of psychiatric symptoms and risk factors for sexual violence and improving quality of life among patients with paraphilic disorders? 3. How do patients with paraphilic disorders describe pathways to care (e.g. perceived obstacles to seeking care) and how do they experience the treatment? The treatment addresses specific sexual problems. It also addresses mental symptoms (e.g. depression and anxiety). A psychologist provides the treatment face to face (on site or video). The aim is to finish the treatment within 12 weeks. The patient will report symptoms on a daily basis. The patient will also be interviewed after completion of treatment. The investigator will pose questions such as "Was there anything that was experienced as particularly helpful in the treatment?", "Was there anything that was not helpful?". The investigator will also ask about treatment seeking behavior with questions such as "What kinds of resources would be helpful if they were available?"

Eligibility Criteria

Inclusion Criteria: 1. Participants included in the study Paraphilic Disorders and Other Conditions With Risk for Sexual Violence: a Case-control Study 2. Deemed to benefit from CBT. 3. Signed informed consent form for participation in the CBT treatment. Exclusion Criteria: 1. Mental condition that could negatively influence either the patient's health or the scientific aspects of the study, e.g., substance use syndrome, other ongoing psychotherapeutic treatment. 2. Initiation of medication or change change of concurrent medication or dosage in the past three months regarding antidepressants, attention deficit hyperactivity disorder medication, cortisone, testosterone, naltrexone, testosterone blockers, or dopamine precursors. Smaller adjustments may in some cases be acceptable (assessed by study psychiatrist).

Contact & Investigator

Central Contact

josephine savard, MD, PhD

✉ josephine.savard@regionstockholm.se

📞 0046812373200

Principal Investigator

josephine Savard

PRINCIPAL INVESTIGATOR

Anova, Karolinska University Hospital, Stockholm, Sweden

Frequently Asked Questions

Who can join the NCT06404684 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Paraphilic Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06404684 currently recruiting?

Yes, NCT06404684 is actively recruiting participants. Contact the research team at josephine.savard@regionstockholm.se for enrollment information.

Where is the NCT06404684 trial being conducted?

This trial is being conducted at Stockholm, Sweden.

Who is sponsoring the NCT06404684 clinical trial?

NCT06404684 is sponsored by Region Stockholm. The principal investigator is josephine Savard at Anova, Karolinska University Hospital, Stockholm, Sweden. The trial plans to enroll 14 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology